SureTrader
Home > Boards > US Listed > Biotechs >

Opko Health Inc (OPK)

OPK RSS Feed
Add OPK Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/18/2018 1:22:23 PM - Followers: 164 - Board type: Free - Posts Today: 0

Opko Health Initiates Phase 3 Trial of Bevasiranib for the Treatment of AMD Wednesday July 11, 8:00 am ET -Trial Designed to Compare Efficacy of Bevasiranib Administered Every 8 Weeks or 12 Weeks with Lucentis(R) Administered Every 4 Weeks- -Represents First-Ever Phase 3 Pivotal Trial of an RNAi Therapeutic- MIAMI, July 11 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced the initiation of the Phase 3 COBALT (Combining Bevasiranib And Lucentis Therapy) clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD.) The multi-national COBALT study is currently open and enrolling patients. The trial will include more than 330 wet AMD patients and will assess whether bevasiranib administered every 8 or 12 weeks is safe and has equivalent efficacy in preventing vision loss as Genentech's Lucentis® administered every four weeks. ADVERTISEMENT Bevasiranib is a first-in-class small interfering RNA (siRNA) drug designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for the vision loss of wet AMD. Bevasiranib is the first therapy based on the Nobel Prize-winning RNA interference (RNAi) technology to advance to Phase 3 clinical trials. "This first-ever Phase 3 trial of an agent based on RNAi technology is an important milestone in this new field. We are proud of the ability demonstrated by our clinical group to have successfully moved this innovative compound through development rapidly and cost effectively," said Philip Frost, M.D., Chairman and CEO of Opko Health. "Currently patients with wet AMD undergo intravitreal injections every four weeks to achieve the vision- preserving benefits of Lucentis, so the potential ability of bevasiranib to achieve similar results while requiring less frequent injections would be an important benefit for these patients who often have limited mobility." "Bevasiranib's demonstrated safety profile, its ability to inhibit the growth of the retinal lesions associated with wet AMD and its potential for prolonged duration are a promising foundation for this pivotal trial," said Lawrence Singerman M.D., founder and Executive Secretary of the Macula Society, Clinical Professor of Ophthalmology at Case University and a Principal Investigator for the Phase 3 study. "Bevasiranib's potential to serve as a long-term maintenance therapy for wet AMD could provide important benefits to patients, and I look forward to helping to assess its utility in this groundbreaking study." "We are very pleased at the enthusiastic reception the COBALT trial has received from retinal centers around the globe," said Denis O'Shaughnessy, Ph.D., Senior Vice President of Clinical Development at Opko. "Retinal physicians are keenly aware of the burden that frequent drug injections places on elderly patients and their families, and they are eager to help test an innovative new approach that has the potential to significantly reduce that burden while preserving patients' vision." About Wet AMD Wet age-related macular degeneration is the leading cause of irreversible vision loss in the developed world and its incidence is growing rapidly. Advanced age is the main risk factor for wet AMD, and it is expected to become an increasingly common condition as the population grows older. An estimated 1.65 million Americans have wet AMD today and an estimated 11 million people worldwide will have AMD by 2013. Until recently, treatments for wet AMD were of limited efficacy. In the search for more effective treatments, researchers targeted VEGF, shown to be a key cause of the excess growth and leakiness of ocular blood vessels that result in loss of vision in these patients. Current VEGF antagonists, such as Lucentis, slow this vision loss, but require injections into the eye every four weeks, a particular issue for elderly patients who often have limited mobility. Opko Health, Inc. Announces Early Termination of Hart-Scott-Rodino Waiting Period for Proposed Purchase of Shares by Dr. Phillip Frost Thursday July 12, 8:00 am ET MIAMI July 12 /PRNewswire-FirstCall/ -- Opko Health Inc. (Amex: OPK - News) today announced that that the U.S. Department of Justice has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the potential acquisition of additional shares of Opko Health common stock by Dr. Phillip Frost, CEO and Chairman of Opko. Dr. Frost has requested clearance to purchase additional shares of Opko Health common stock, which this action by the Justice Department now makes feasible.
SureTrader
OPK
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
OPK News: Statement of Changes in Beneficial Ownership (4) 04/20/2018 06:41:41 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/17/2018 06:54:59 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/17/2018 06:52:58 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/16/2018 06:50:47 AM
OPK News: Statement of Changes in Beneficial Ownership (4) 04/16/2018 06:49:53 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#6004   Hi Joe, that's aside from the fund or tredenwater2 04/18/18 01:22:23 PM
#6003   1.94M in the float? I think I am joe_techi 04/17/18 11:15:00 PM
#6002   Joe, I suppose a doctor who has made billions terry hallinan 04/17/18 10:43:12 PM
#6001   Agreed. The insider buying (besides Frost and maybe joe_techi 04/17/18 07:49:01 PM
#6000   Yeah, Joe, but what would insiders know compared terry hallinan 04/17/18 06:44:39 PM
#5999   background info joe_techi 04/17/18 01:08:26 PM
#5998   Hi Buckiii2 tredenwater2 04/15/18 06:40:54 AM
#5997   Does this CEO buy stock every day or so? terry hallinan 04/13/18 04:09:38 PM
#5996   Does this CEO buy stock every day or buckiii2 04/13/18 03:21:13 PM
#5995   Hope it works for you!!! And others!! now invest 04/13/18 12:13:01 AM
#5994   I am thinking... I was probably more!!!! now invest 04/13/18 12:10:44 AM
#5993   Thanks, Joe. terry hallinan 04/12/18 10:55:10 PM
#5992   Good Luck, Now Invest. terry hallinan 04/12/18 10:35:37 PM
#5991   Good luck! I wish I could do the game7alcs 04/12/18 06:41:46 PM
#5990   Good for you I been around since 2009 and Juice555 04/12/18 04:08:57 PM
#5989   CT Order....Based on representations by OPKO Health, Inc. joe_techi 04/12/18 03:53:58 PM
#5988   WELL...I AM FREE !!! AFTER LIKE 7 now invest 04/12/18 11:04:45 AM
#5987   Is Dr. Frost and Associates close to owning tredenwater2 04/12/18 08:46:29 AM
#5986   Unless they start making money this will continue terry hallinan 04/05/18 06:44:59 AM
#5985   Not a chance in my opinion. Unless they game7alcs 04/04/18 06:02:50 PM
#5984   I believe we are highly shorted, hope shorts traderjack1 04/04/18 05:08:43 PM
#5983   They post almost every day. He continues to game7alcs 04/04/18 04:17:36 PM
#5982   New director to company. Updated 8-k Chris2125 04/04/18 04:16:45 PM
#5981   Don't know but a form 4 from Frost buckiii2 04/04/18 04:12:10 PM
#5980   What’s cooking here? WovenO2 04/04/18 02:09:23 PM
#5979   Eloxx Pharmaceuticals Reports Full Year 2017 Financial and terry hallinan 03/19/18 11:58:56 AM
#5978   10 mil even traded. Kind of strange? game7alcs 03/19/18 07:39:31 AM
#5977   3,265,933 shares purchased on the buy side at close. homeboy 03/17/18 12:41:30 PM
#5976   * * $OPK Video Chart 03-16-18 * * ClayTrader 03/16/18 04:45:25 PM
#5975   What are your thoughts on the 4K test terry hallinan 03/16/18 09:45:47 AM
#5974   You bet! Gilbert801027 03/16/18 09:33:15 AM
#5973   News on 4K effectiveness.... see above. Maybe a now invest 03/16/18 08:53:11 AM
#5972   In The War Against High Drug Prices, Some terry hallinan 03/12/18 03:54:14 PM
#5971   Opko Health Short Interest conix 03/12/18 01:43:45 PM
#5970   De nada. terry hallinan 03/09/18 09:38:13 PM
#5969   Thanks for taking the time Sone 03/09/18 08:44:22 PM
#5968   Why the pop today? terry hallinan 03/09/18 06:38:58 PM
#5967   Why the pop today? Sone 03/09/18 05:05:24 PM
#5966   Thanks for that article Gilbert !! now invest 03/09/18 09:59:49 AM
#5965   Gilbert, Thank you. terry hallinan 03/08/18 05:48:18 PM
#5964   http://sharesleuth.com/investigations/2018/03/pretenders-and-ghosts-stealth-prom Gilbert801027 03/08/18 04:47:09 PM
#5963   FWIW Zacks Equity Research terry hallinan 03/08/18 03:11:18 PM
#5962   How come you have no competition here? learning curve 03/06/18 02:15:23 AM
#5961   :-) terry hallinan 03/05/18 11:39:00 AM
#5960   Zacks Investment Research cut shares of Opko Health joe_techi 03/05/18 10:46:41 AM
#5959   Opko Health (OPK) in Focus: Stock Moves 6% Higher[/colo terry hallinan 03/05/18 10:34:19 AM
#5958   Rx For the Frights - Treatment For Warts, terry hallinan 03/03/18 09:21:11 AM
#5957   OPKO HEALTH GETS A BUY RATING FROM CANTOR FITZGERALD homeboy 03/03/18 01:15:51 AM
#5956   Good luck to you, Game7. terry hallinan 03/01/18 10:58:55 PM
#5955   I have to have hope. I am too game7alcs 03/01/18 09:23:45 PM
PostSubject